Copyright
©The Author(s) 2021.
World J Clin Cases. Nov 6, 2021; 9(31): 9406-9416
Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9406
Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9406
Table 1 Comparison of demographic and clinical characteristics for deep venous thrombosis after artificial liver support system in Stage I
| Parameters | DVT (n = 12) | No-DVT (n = 220) | Statistics | P value |
| Gender, n (%) | ||||
| Man | 7 (58.3) | 165 (75) | 1.649 | 0.306 |
| Woman | 5 (41.7) | 55 (25) | ||
| Age (yrs), n (%) | ||||
| < 40 | 2 (18.2) | 51 (28.7) | 7.17 | 0.027 |
| < 60, ≥ 40 | 4 (36.4) | 101 (56.7) | ||
| ≥ 60 | 5 (45.5) | 26 (14.6) | ||
| Mean arterial pressure (mmHg), mean ± SD | 83.45 ± 14.47 | 84.11 ± 13.26 | 0.768 | 0.707 |
| Fasting plasma glucose (mmol/L), mean ± SD | 5.43 ± 1.51 | 5.41 ± 1.65 | 0.332 | 0.542 |
| Smoke, n (%) | ||||
| No | 7 (58.3) | 142 (64.5) | 0.197 | 0.759 |
| Yes | 5 (41.7) | 78 (35.5) | ||
| Catheterization mode, n (%) | ||||
| Jugular vein | 0 (0) | 72 (30) | 5.09 | 0.022 |
| Femoral vein | 12 (100) | 168 (70) | ||
| Times of successful catheterization, n (%) | ||||
| One | 3 (25) | 151 (71.9) | 16.669 | 0 |
| Two | 4 (33.3) | 41 (19.5) | ||
| Three and more | 5 (21.7) | 18 (8.6) | ||
| Heparin therapy, n (%) | ||||
| No | 3 (25) | 56 (25.5) | 0.01 | 0.971 |
| Yes | 9 (75) | 164 (74.5) | ||
| Procoagulant therapy, n (%) | ||||
| No | 8 (67.7) | 164 (74.5) | 0.368 | 0.513 |
| Yes | 4 (33.3) | 56 (125.5) | ||
| Etiology, n (%) | ||||
| Virus hepatitis | 9 (75) | 133 (60.5) | 1.028 | 0.795 |
| Drug injury | 1 (8.3) | 29 (13.2) | ||
| Autoimmune liver disease | 1 (8.3) | 24 (11.8) | ||
| Others | 1 (8.3) | 32 (14.5) | ||
| ALSS times, n (%) | ||||
| < 3 | 3 (25) | 61 (27.7) | 7.344 | 0.025 |
| ≥ 3, < 5 | 5 (21.7) | 139 (63.2) | ||
| ≥ 5 | 4 (33.3) | 20 (9.1) | ||
| Activity status, n (%) | ||||
| Free activities | 0 (0) | 23 (10.5) | 10.773 | 0.013 |
| Less than 4 h/d | 2 (16.7) | 89 (40.5) | ||
| Less than 1 h/d | 4 (33.3) | 74 (33.6) | ||
| Strict bed rest | 6 (50.0) | 32 (15.5) | ||
| Ascites status, n (%) | ||||
| No | 3 (25) | 67 (28.1) | 0.923 | 0.82 |
| Mild | 4 (33.3) | 79 (37.6) | ||
| Moderate | 3 (25) | 56 (25.7) | ||
| Severe | 2 (16.7) | 19 (8.6) | ||
| Bleeding, n (%) | ||||
| No | 8 (67.7) | 153 (69.5) | 0.436 | 0.833 |
| Yes | 4 (33.3) | 67 (30.5) | ||
| Hepatic encephalopathy, n (%) | ||||
| No | 6 (54.5) | 148 (67.3) | 1.933 | 0.385 |
| I-II | 4 (33.3) | 55 (25.0) | ||
| III-IV | 2 (17.5) | 17 (7.7) | ||
| Infection, n (%) | ||||
| No | 4 (33.3) | 144 (65.5) | 5.083 | 0.031 |
| Yes | 8 (67.7) | 76 (34.5) | ||
| Complicated by other serious diseases, n (%) | ||||
| No | 8 (67.7) | 174 (79.1) | 1.039 | 0.294 |
| Yes | 4 (33.3) | 46 (20.9) | ||
| Body mass index (kg/m2), n (%) | ||||
| < 23 | 2 (20.0) | 77 (35) | 2.262 | 0.332 |
| ≥ 23, < 25 | 4(40.0) | 97 (44.1) | ||
| ≥ 25 | 4 (40.0) | 46 (20.9) | ||
| Platelet count (109/L), n (%) | ||||
| < 100 | 3 (25) | 99 (45) | 2.258 | 0.277 |
| ≥ 100, < 300 | 8 (66.7) | 95 (43.2) | ||
| ≥ 300 | 1 (8.3) | 16 (11.8) | ||
| Total bilirubin (μmol/L), mean ± SD | 234.45 ± 155.12 | 231.65 ± 132.86 | 1.476 | 0.583 |
| Alanine aminotransferase (U/L), mean ± SD | 256.82 ± 243.455 | 294.65 ± 341.36 | 1.20· | 0.578 |
| D-dimer (ng/mL), n (%) | ||||
| < 200 | 1 (8.3) | 88 (40) | 12.232 | 0.002 |
| ≥ 200, < 500 | 3 (25.9) | 82 (37.3) | ||
| ≥ 500 | 8 (66.7) | 50 (22.7) | ||
| Fibrinogen (g/L), mean ± SD | 1.25 ± 0.43 | 1.33 ± 1.12 | 2.554 | 0.212 |
| International normalized ratio, n (%) | ||||
| < 1.5 | 0 (0) | 0 (0) | 0.215 | 0.767 |
| ≥ 1.5, < 2 | 6 (54.5) | 125 (56.8) | ||
| ≥ 2 | 6 (45.5) | 85 (43.2) | ||
- Citation: Ye Y, Li X, Zhu L, Yang C, Tan YW. Establishment of a risk assessment score for deep vein thrombosis after artificial liver support system treatment. World J Clin Cases 2021; 9(31): 9406-9416
- URL: https://www.wjgnet.com/2307-8960/full/v9/i31/9406.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i31.9406